Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of CKD-841 vs Leuplin in Postmenopausal Females
NCT03233932Phase 1Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Apr 2016
- Primary completion
- Jul 2017
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of leuprolide in endometriosis, Uterine Fibroids (UF), prostate cancer (PCa) and 1 more (2 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Peak Plasma Concentration, Area Under the Curve to last measurement and 7 more. Started Apr 2016; status: completed.
02
Drugs
leuprolide
03
Conditions
endometriosisUterine Fibroids (UF)prostate cancer (PCa)breast cancer
Beyond the preview
Go deeper on NCT03233932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03233932.